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Abstract 
Background: Long‑acting artemisinin‑based combination therapy (LACT) offers the potential to prevent recurrent 
malaria attacks in highly exposed children. However, it is not clear where this advantage will be most important, and 
deployment of these drugs is not rationalized on this basis.
Methods: To understand where post‑treatment prophylaxis would be most beneficial, the relationship between 
seasonality, transmission intensity and the interval between malaria episodes was explored using data from six cohort 
studies in West Africa and an individual‑based malaria transmission model. The total number of recurrent malaria 
cases per 1000 child‑years at risk, and the fraction of the total annual burden that this represents were estimated for 
sub‑Saharan Africa.
Results: In settings where prevalence is less than 10 %, repeat malaria episodes constitute a small fraction of the 
total burden, and few repeat episodes occur within the window of protection provided by currently available drugs. 
However, in higher transmission settings, and particularly in high transmission settings with highly seasonal transmis‑
sion, repeat malaria becomes increasingly important, with up to 20 % of the total clinical burden in children estimated 
to be due to repeat episodes within 4 weeks of a prior attack.
Conclusion: At a given level of transmission intensity and annual incidence, the concentration of repeat malaria 
episodes in time, and consequently the protection from LACT is highest in the most seasonal areas. As a result, the 
degree of seasonality, in addition to the overall intensity of transmission, should be considered by policy makers when 
deciding between ACT that differ in their duration of post‑treatment prophylaxis.
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Background
The burden of malaria is not shared equally in endemic 
areas—some children experience repeated attacks of 
malaria while others remain healthy [1, 2]. Children who 
have multiple episodes of clinical malaria may be more 
likely to develop severe disease or severe anaemia [2–5], 
and recurrent malaria after discharge may lead to further 
severe morbidity in children who have been admitted to 
hospital [6, 7]. Repeated episodes of malaria may make 
children more susceptible to, or increase the severity of, 
other conditions such as invasive bacteraemia [8], and 
may also lead to poor school performance [9].
Artemisinin-based combination therapy (ACT) used 
for case management of malaria provides protection 
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against a subsequent attack in the immediate period 
after treatment, because parasites that emerge from the 
liver while sufficient concentrations of the partner drug 
remain present in the blood will be killed. The duration 
of this post-treatment prophylaxis (PTP) depends on the 
pharmacokinetics and pharmacodynamics of the drug, 
as well as the resistance patterns in the parasite popula-
tion to which individuals are exposed [10]. Thus, some 
repeat episodes of malaria will be prevented by use of any 
effective drug, but the number of episodes prevented will 
be greater where a longer-acting drug is used to manage 
the initial episode [11] and where the interval between 
attacks is short. Several long-acting forms of ACT 
(LACT) are now available, including dihydroartemisinin-
piperaquine (DHA-PQ) and artesunate-mefloquine (AS-
MQ), which provide several additional weeks of PTP 
compared to shorter-acting drugs. However, choice of 
first line treatment is not currently rationalized to exploit 
this benefit to its full potential.
The interval between malaria attacks will be short in 
high transmission settings, where reinfection is very 
common, until sufficient immunity is acquired to pre-
vent disease. Cohort studies in highly endemic areas have 
shown a regular recurrence of symptomatic malaria, with 
intervals dependent on the drug used for treatment of the 
initial attacks [12–14]. A randomized trial in an area of 
high, seasonal transmission in Mali found that children 
who received artesunate plus a longer-acting partner 
drug (either amodiaquine or sulfadoxine-pyrimethamine) 
for each of their malaria episodes experienced fewer epi-
sodes over a 2 year period than children treated with the 
shorter-acting ACT, artemether-lumefantrine [11]. A 
recent model-based cost effectiveness study found that 
DHA-PQ would be more effective and cost-effective 
than artemether-lumefantrine in areas where transmis-
sion is high and seasonal [15]. The benefit of long-acting 
drugs may be greatest in high transmission, seasonal set-
tings for a number of reasons. Firstly, areas with a high 
annual burden and a short season imply very high inci-
dence rates (and very short intervals between episodes) 
during the season (Fig.  1). Secondly, in highly seasonal 
settings, a few weeks of PTP from a LACT may reflect a 
large proportion of the total time exposed each year: in 
the extreme case, in a setting with a transmission season 
1 month in length, there should be no recurrent malaria 
if a drug providing more than 1 month of PTP is used for 
case-management. Finally, immunity may develop more 
slowly in seasonal settings due to gaps in exposure and 
decay in immune responses during the dry season.
However, to explore this further, and to generalize these 
findings to other drug combinations and to other interven-
tions that could potentially be deployed to reduce the bur-
den of repeated episodes of malaria, a better understanding 
of how seasonality and transmission intensity affect the 
epidemiology of repeated episodes of malaria is needed. 
This information could help inform policy-makers as to the 
likely importance of repeated episodes of malaria within 
a specific context, based on these underlying epidemio-
logical drivers. In the present study, the timing and interval 
between repeat malaria episodes were estimated using data 
from six cohort studies in West Africa. An individual-based 
model of malaria transmission across sub-Saharan Africa 
was then used to explore the effects of transmission inten-
sity and seasonality on the timing of repeat malaria across a 
range of epidemiological settings.
Methods
Data
Data on malaria incidence were analysed from six obser-
vational or experimental cohort studies in West Africa, 
conducted in Kintampo, Ghana [16]; Navrongo, Ghana 
[17]; Boussé, Burkina Faso [18, 19]; Kati district, Mali [20, 
21]; Farafenni, The Gambia (Milligan, unpublished data) 
and Niakhar, Senegal [22]. Each of the field studies was 
approved by the Ethics Committee of the London School 
of Hygiene and Tropical Medicine and in the appropriate 
country, except for the Gambia cohort study which was 
approved by the MRC Gambia Ethics Committee. Further 
details of the studies and the sites are given in Table 1 and 
Additional file 1. In brief, these sites represent a range of 
transmission intensity, with cross-sectional prevalence 
ranging from 13 to 64 %, and a range of seasonality pat-
terns, from year-round transmission in Kintampo, Ghana 
to highly seasonal transmission in the Gambia and Sen-
egal. Genotyping was not undertaken to allow new infec-
tions to be distinguished from repeat attendances for 
the same clinical attack, or treatment failure, so to avoid 
double counting of the same clinical attack, malaria epi-
sodes within 7 days of a prior episode were not counted; 
this may exclude some genuine re-attendances for treat-
ment failure. The seasonality in the incidence of malaria 
was then quantified, and the distribution of the intervals 
between malaria episodes examined as described below.
Seasonality
The Markham seasonality index (MSI) [23] has previously 
been used to characterize malaria seasonality [24]. Full 
details are given in Additional file 2. In brief, the malaria 
incidence in each month is expressed as a vector, with a 
(different) fixed direction for each month, and with the 
length of the vector corresponding to the fraction of the 
annual incidence occurring in that month. Summation 
of the 12 monthly vectors gives a resultant vector, i.e. the 
finishing point back to the origin. The length of the result-
ant vector divided by the total length of all 12 monthly 
vectors gives the MSI (taking values ranging from 0, in 
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the case where all months have equal incidence, and 1, in 
the case where all incidence occurs within 1 month). The 
direction of the resultant vector indicates the month in 
which the peak in incidence occurs. The MSI was calcu-
lated for each of the six studies.
Timing of repeated episodes
The distribution of recurrent malaria episodes was 
inspected visually by constructing a histogram of the inter-
val between episodes experienced by the same individual 
(based on date of first contact for each unique malaria 
episode). The mean interval between episodes was then 
obtained using the Kaplan–Meier estimate of the mean 
survival time among those who experienced a subsequent 
episode before the end of the follow-up period.
For the time varying hazard h(t), the survivor function 
for person treated on day x is
where the time elapsed time from treatment is measured 
in days, x = 0 and T = 365.
S(x,T ) = exp
(
−
∫
T
x
h(t)dt
)
The mean interval is then the area under the survival 
curve i.e.
and the average incidence over the year is the mean of 
h(t).
Modelling
Having calculated these measures of seasonality and 
distribution of intervals between of repeat episodes 
for the six sites, an individual-based model (IBM) of 
Plasmodium falciparum described previously [25] was 
used to generalize these findings. This model describes 
the full transmission cycle of P. falciparum between 
humans and mosquitoes, as well as disease progres-
sion in humans, and has been fitted to extensive data 
on parasite prevalence determined by microscopy and 
polymerase chain reaction (PCR), and episodes of 
uncomplicated malaria by age and transmission set-
ting across Africa [25, 26]. Heterogeneity in malaria 
risk is simulated by randomly assigning individuals at 
birth to experience different relative biting rates [25]. 
∫
T
0
S(t)dt
Fig. 1 Illustration of the effect of seasonality on timing of malaria infections, and the benefit of post‑treatment prophylaxis. EIR entomological 
inoculation rate, PTP post‑treatment prophylaxis. Simplified representation of the effect of seasonality on timing of malaria infections. Sites A and B 
have the same annual EIR (6 infections per person per year). However, the monthly EIR in the seasonal setting (scenario B) is twice that in the peren‑
nial setting (scenario A). The monthly EIR during the transmission season in site B is the same as a perennial setting with an annual EIR of 12 (site C). 
Due to post‑treatment prophylaxis provided by case‑management for malaria, some malaria infections that occur soon after a previous episode will 
be prevented. This is more likely to occur where infection rates are higher, and where malaria infections occur close together in time. In seasonal 
settings, the length of PTP also becomes large in relation to the length of the season. This suggests that seasonal settings may have more prevent‑
able malaria than perennial settings with an equivalent annual EIR. Additional complications dealt with in this paper include realistic seasonality 
patterns, heterogeneity in malaria risk between individuals, immunity (acquisition of which may differ in seasonal and non‑seasonal settings) and 
variable duration of protection from drugs used for case‑management
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The model also incorporates the impact of insecticide-
treated nets (ITNs). Anti-disease immunity, which 
reduces the probability of a blood-stage infection 
resulting in a clinical episode, is acquired at a rate that 
depends on exposure [25, 27]. The assumed paramet-
ric form of this immunity in the model gives rise to a 
lengthening of the interval between successive malaria 
attacks in areas of high endemicity, particularly among 
the most exposed sub-groups within a population who 
have higher exposure, and who therefore acquire pro-
tective immunity faster relative to their neighbours. 
The model has been fitted to age-incidence curves from 
23 sites in Africa [26] but has not previously been com-
pared to longitudinal patterns of repeat episodes. For 
this analysis, the timing of clinical episodes of malaria 
predicted by the model (i.e. when infection is sympto-
matic, and treatment is sought) were recorded for each 
individual in the simulation, to create a dataset of the 
timing of treated clinical episodes comparable to those 
from the six studies in West Africa.
Simulations were run using transmission and season-
ality parameters appropriate to the first administrative 
unit (the largest sub-division within each country) within 
which the studies were located, to investigate if the model 
could approximately replicate the patterns seen in the 
six data sets in terms of seasonality and concentration of 
malaria episodes. Duration of post-treatment prophylaxis 
after treatment for malaria in each simulation was chosen 
to approximate that provided by the drug used in each 
study. Simulations were restricted to the same age group 
and with prevalence and levels of ITN coverage similar to 
those in the original studies.
Model seasonality
Seasonality in transmission in the model is driven 
by temporal fluctuations in rainfall and temperature, 
which determine the ability of the environment to sup-
port development of mosquito larvae, referred to as lar-
val carrying capacity (LCC) [28]. The LCC function was 
integrated by month for each of the 576 first administra-
tive areas across Africa to estimate the MSI as described 
above, giving values of the MSI ranging from 1 to 91 %. 
However, all sites with an MSI <10 % were bimodal sites 
with two equal peaks spaced approximately 6  months 
apart. Nine sites were chosen representing each 10  % 
interval of the MSI between 10 and 90 % for further anal-
ysis, focusing on those without bimodal seasonality pat-
terns, which were considered separately (see Additional 
file 3). To confirm that the seasonality in larval carrying 
capacity was reflected in incidence of clinical malaria 
predicted by the model, the Markham seasonality index 
was also calculated for symptomatic attacks of malaria 
predicted by the model in the nine sites.
Modelling seasonality in different transmission intensity 
settings
For each of the seasonality patterns identified as 
described above (i.e. with MSI between 10 and 90 %), sce-
narios were simulated with mean annual parasite preva-
lence in 2–10 year old children of 5, 10, 20, 40 and 60 %, 
creating a 9 × 5 matrix of seasonality versus transmission 
intensity. For each of the 45 scenarios, all other param-
eters apart from the seasonality pattern and prevalence 
in 2–10 year olds were held constant. The set of param-
eters from the Upper East Region of Ghana (the first 
administrative unit in which the Navrongo study site is 
located) were used. This site was chosen because the epi-
demiology in this location has been well-characterized 
e.g. [29–35] and because this site was one of a number of 
sentinel sites used in assessing the fit of the model [25]. 
For all scenarios in the simulation, duration of post-treat-
ment prophylaxis after case-management for malaria was 
assumed to be short (mean duration of 10 days).
Histograms showing the distribution of intervals 
between episodes were produced, and the estimated 
mean interval between malaria episodes calculated for 
each of the modelled scenarios using the Kaplan–Meier 
approach as described above. To understand the relative 
importance of seasonality and endemicity on the timing 
of repeat malaria episodes, the mean interval between 
episodes was plotted against the Markham seasonality 
index for each level of prevalence.
To explore the possible effect of post-treatment proph-
ylaxis of varying duration, the model was used to esti-
mate, for each scenario, the number of repeat malaria 
episodes that occur within 28, 42, 56 and 70 days of a pre-
vious attack, and the fraction of the annual burden that 
this represents. The result for the corresponding model 
scenario was then matched (in terms of seasonality and 
prevalence category) to indicate the absolute and relative 
importance of repeat malaria in these different periods, 
for each first administrative area in Africa.
Results
Data from cohort studies
In the cohort studies in West Africa, the seasonality in 
clinical malaria episodes increased moving from South 
to North, following the known patterns in seasonality of 
rainfall in the Sahel and sub-Sahel [36]. The Markham 
seasonality index (MSI), used to quantify seasonality 
in malaria incidence, was as follows: Kintampo, Ghana 
[16]: 42.8 %; Navrongo, Ghana [17]: 54.5 %; Boussé, Bur-
kina Faso [18, 19]: 74.3 %; Kati, Mali [20, 21]: 82.3 %, Far-
afenni, The Gambia (Milligan, unpublished data): 85.5 %, 
Niakhar, Senegal [22]: 79.0 %. A graphical representation 
of the Markham seasonality index is shown for each site 
in Additional file  4.
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The distribution of the intervals between repeat epi-
sodes of malaria for each site is shown in Fig. 2. Moving 
from South to North (i.e. from less seasonal to more sea-
sonal settings) the mean interval between episodes, esti-
mated using the Kaplan–Meier method, decreased: mean 
interval, 74.6 (95 % CI 71.1, 78.0) days in Kintampo, 66.1 
(95 % CI 60.6, 71.6) days in Navrongo, 52.4 (95 % CI 48.0, 
56.7) days in Boussé, 43.4 (95  % CI 40.1, 46.7) days in 
Kati, 42.3 (95 % CI 37.0, 47.5) days in Farafenni, and 50.9 
(95 % CI 49.0, 52.8) days in Niakhar.
A plot of the observed MSI against the mean inter-
val between episodes is shown in Fig.  3. This suggests 
that the average interval between episodes decreases as 
seasonality increases, although interpretation of this 
based on the data alone is complicated by differences in 
transmission intensity, and other differences between 
the sites, including the use of drugs used for case-man-
agement. This was chloroquine or chloroquine plus 
sulfadoxine-pyrimethamine in the three earlier studies 
(long-acting but likely subject to some resistance) and 
an ACT in the three latter studies (highly effective but 
shorter-acting).
Model simulations
The MSI of the larval carrying capacity (the suitability of 
the environment for development of malaria vectors [28]) 
is shown for each of the 576 first administrative areas in 
Africa simulated by the model in Fig.  4. Relatively few 
locations showed a strong degree of bimodality in malaria 
transmission; these are dealt with separately in Additional 
file 3 and summarized below. Seasonality profiles and the 
corresponding Markham seasonality polygons for the 
sites representing 10  % intervals of the MSI (from 10 to 
90 %) are shown in Additional files 5, 6. The model pre-
dictions of the MSI was very close to the observed values 
for the locations in which the six studies were conducted 
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The mean interval between malaria episodes, in days, was 50.9 (95 % CI 49.0, 52.8) days in Niakhar, 42.3 (95 % CI 37.0, 47.5) days in Farafenni, 43.4 
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(Fig.  3b). The correlation between seasonality in larval 
carrying capacity (LCC) input into the model and season-
ality in malaria incidence predicted by the model was very 
strong at all levels of prevalence (Additional file  7). The 
mean interval between malaria episodes predicted by the 
model was also similar for the locations where the cohort 
studies were conducted (Fig. 3c).
Figure  5 shows the estimated mean interval between 
episodes plotted against the Markham seasonality index 
for each of the 45 scenarios modelled (nine seasonal-
ity patterns (10–90 %), and five prevalence levels (5, 10, 
20, 40 and 60  % in 2–10  year olds). The distribution of 
intervals between malaria episodes is shown in Addi-
tional file 8. Malaria episodes occur in closer succession 
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in higher prevalence settings, where more infections 
occur per unit time. At a given prevalence, the average 
interval between repeat episodes decreases with increas-
ing seasonality, and is always shortest in the most sea-
sonal transmission settings. In particular, a large part of 
the burden of repeat malaria episodes occurs soon after 
a previous episode in highly seasonal, high prevalence 
areas. Bimodality increases the average interval between 
episodes compared to unimodal seasonal settings of sim-
ilar endemicity, because there are two periods when cases 
are more likely to occur, separated by a period of lower 
risk (Additional file 3).
Figure  6 shows the burden of repeat malaria episodes 
within 28 and 42  days of a previous attack in absolute 
terms, as well as the incremental increase in the bur-
den of repeat malaria between 28 and 42  days after the 
preceding episode. Figure 7 shows the burden of repeat 
malaria within 28 and 42  days as a fraction of the total 
malaria burden (all episodes, including first episodes) 
in children under 5  years of age. The highest burden 
of repeat malaria occurring soon after a previous epi-
sode appears to be in the Sahel and sub-Sahel regions of 
Africa, where malaria transmission is intense and highly 
seasonal. Repeat malaria also appears to be important in 
a seasonal focus encompassing parts of Malawi, Mozam-
bique and Southern Tanzania, and in areas of perennial 
transmission with a very high burden in Eastern Uganda.
Interventions able to tackle the burden of repeat 
malaria soon after treatment are likely to have an impor-
tant impact on malaria burden in highly endemic set-
tings, and particularly in highly endemic and highly 
seasonal settings. In such settings, repeat malaria within 
28 days of a previous episode constitutes up to 20 % of 
the overall malaria burden in children (Additional file 9). 
Within 42  days, this share of the overall burden rises 
to around 30  %. At 60  % prevalence, an estimated 250 
cases per 1000 children per year occur within 42 days of 
a prior attack in perennial settings, rising to 1000 cases 
per 1000 children in highly seasonal settings (Additional 
file  10). In such areas, the incremental effect of a drug 
providing an additional 2 weeks of PTP (42 days versus 
28  days) could prevent in excess of 200 cases per 1000 
children, per year.
In areas with highly seasonal transmission and moder-
ate-high transmission (e.g. 2–10  year old prevalence of 
40  %), repeat malaria can, relative to non-seasonal set-
tings with substantially higher prevalence (2–10 year old 
prevalence of 60 %), account for a higher number of cases 
(e.g. Additional file  10) and a higher proportion of the 
overall malaria burden (Additional file 9).
In settings with a prevalence in 2–10 year old children 
less than 20 %, repeat malaria is relatively unimportant. 
This is partly because there is a small absolute number of 
repeat episodes (Additional file  10), and partly because 
repeat episodes soon after a previous attack constitute a 
small fraction of the overall burden (Additional file 9).
While the burden within 56 and 70 days of a prior epi-
sode is larger than that within 28 and 42 days, the incre-
mental increase in the burden with increasing time since 
Fig. 4 Markham seasonality index by first administrative area. Figure 
shows Markham seasonality index for larval carrying capacity (LCC) 
for each first administrative area (the largest administrative sub‑
division within country. Black areas show those with strongly bimodal 
seasonality patterns (see Additional file 3 for details)
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the previous episode is progressively smaller as the post-
treatment interval increases (Additional files 11, 12). In 
the most seasonal settings (MSI 90  %), these incremen-
tal values are smaller than in slightly less seasonal set-
tings (MSI 70, 80 %). This is because the distribution of 
repeat malaria episodes peaks very sharply soon after 
a previous episode in extremely seasonal settings, and 
because malaria risk becomes very small when the post-
episode window extends into the dry season. The advan-
tage of LACTs with a longer mode of action than those 
currently available (e.g. an ACT that provided 10 weeks 
of PTP) may therefore be greater in settings where the 
distribution of repeat malaria episodes is spread slightly 
more evenly over time (i.e. high burden and seasonal, but 
not extremely seasonal). Other than where transmission 
is extremely seasonal, and particularly in perennial set-
tings, longer PTP is always likely to be advantageous as 
although second events may occur close to the preceding 
episode in high transmission settings, subsequent epi-
sodes may also be prevented.
Fig. 6 Burden of repeat malaria episodes per 1000 children by first administrative unit across Africa. Burden of malaria episodes per 1000 children 
that occur within a 28 days and b 42 of a prior episode. c shows the additional burden per 1000 children that occurs between 28 and 42 days after 
a previous episode
Fig. 7 Percentage of malaria burden in children occurring within 28 and 42 days by first administrative unit across Africa. Fraction of all malaria epi‑
sodes in children under 5 years of age predicted to occur within a 28 days and b 42 of a prior episode. c shows the difference in the overall fraction 
of episodes among children that occurs between 28 and 42 days after a previous episode
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Discussion
This analysis investigated the burden of repeated malaria 
episodes and the interval between successive episodes 
in cohort studies conducted in a range of epidemiologi-
cal settings in West Africa, and used a model to esti-
mate the effects of seasonality and transmission on the 
amount and timing of repeat malaria episodes across 
the continent. These results show that seasonality has an 
important effect on the distribution of recurrent malaria 
episodes, and should be considered alongside overall 
transmission intensity when deciding between different 
regimens for the case-management of malaria.
Repeated malaria attacks within a short time frame are 
not common where malaria transmission is low, and very 
few repeat episodes occur within the period of post-treat-
ment prophylaxis provided by currently available drugs. 
This means that the additional benefit of a long-acting 
ACT over a shorter-acting drug in low transmission set-
tings is likely to be minimal, and other factors such as 
cost, simplicity of dosing, tolerability and local resist-
ance patterns to ACT partner drugs are likely to be more 
important considerations. Where malaria transmission is 
higher, repeated episodes of malaria are more common, 
and a larger fraction of the annual burden occurs within 
the period of post-treatment prophylaxis provided by 
longer-acting ACT, and therefore might be prevented if 
these regimens were used in place of shorter-acting regi-
mens. In higher transmission settings, the burden is also 
larger in absolute terms, and the burden averted is also, 
therefore, likely to be larger.
At a given level of transmission intensity, the fraction 
of episodes occurring within a fixed time period after a 
previous attack increases in a non-linear fashion with 
increasing seasonality. This is plausible as in settings 
with a short season, any recurrent malaria must occur 
relatively close to a preceding episode, and because, to 
achieve a similar level of transmission in a shorter period, 
the transmission intensity must be higher during the sea-
son. Seasonality may also lead to more recurrent malaria 
because immunity is not continuously boosted as in per-
ennial areas [37, 38] thus the development of the anti-dis-
ease immunity that reduces the probability of developing 
symptoms upon infection is delayed relative to perennial 
settings.
It is not certain how long protection against clini-
cal malaria after LACT lasts, but a reasonable estimate 
might be between 4–8  weeks depending on the drug 
used, compared to 2–3  weeks for a shorter-acting ACT 
such as artemether-lumefantrine or artesunate-amo-
diaquine [12, 15, 39, 40]. These results show that the 
increase in the number of malaria episodes occurring 
between 28 and 42 days after a preceding attack was sub-
stantial in certain settings, suggesting that the additional 
prophylaxis will make important changes to the burden. 
This may be an underestimate if protection from a short-
acting ACT lasts less than 28 days, or if protection from 
a LACT lasts longer than 6 weeks, or both. The decision 
to switch to ACT from non-ACT was primarily made on 
the basis of dramatic improvements in curative efficacy 
[41]. However, when choosing between the artemisinin-
based combinations that are now available, all of which 
have similarly high curative efficacy, more focus should 
be given to the potential benefits other than cure.
Since long-acting ACT appears to be of most value in 
areas of high and seasonal transmission, there is some 
overlap with seasonal malaria chemoprevention (SMC), 
which has recently been recommended in highly sea-
sonal areas of the Sahel and sub-Sahel with high malaria 
burdens [42]. SMC consists of monthly courses of sulf-
adoxine-pyrimethamine plus amodiaquine, and thus 
precludes use of two of the current ACTs: AS-SP or 
AS-AQ. However, the use of long-acting ACT for treat-
ment, such as DHA-PQP or AS-MQ, may complement 
the SMC strategy, since a child with severe acute illness 
such as malaria will not receive a particular monthly 
course of SMC [42]. A long-acting ACT for case manage-
ment would help avoid the situation where experiencing 
malaria once predisposes a child to experiencing malaria 
again later in the transmission season by preventing them 
being protected by SMC.
This study has a number of limitations inherent to a 
model-based generalization of a more complex prob-
lem. Heterogeneity in exposure to malaria is likely to 
be influential, since this affects how unevenly malaria 
is shared between individuals, with the most exposed 
individuals in a particular setting most likely to experi-
ence recurrent malaria in a short period of time. Simi-
larly, acquired immunity will affect the interval between 
malaria episodes. Acquisition of immunity may differ in 
highly seasonal settings due to waning of protection dur-
ing long periods without exposure, and there being some 
redundancy in additional infections during the transmis-
sion season among individuals who are currently or have 
recently been infected; both heterogeneity and acquisi-
tion of immunity are captured by the model [25], but it 
is not easy to capture these patterns within data in order 
to validate these effects. However, the consistency of the 
patterns of repeat malaria seen in real data and the model 
estimates at different levels of transmission suggest that 
the modelling of heterogeneity and immunity do not 
pose a major problem in terms of the overall interpreta-
tion. The approach used in the present analysis focused 
on true malaria cases that presented for treatment, 
which in practice may not all be treated for malaria, 
but also ignores use of anti-malarials for non-malaria 
cases, which may provide some benefits. The Markham 
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seasonality index used in this study can underestimate 
the level of seasonality in areas with bimodal patterns, 
but the approach used here, which identified and inves-
tigated bimodality separately, suggests that areas with a 
high degree of bimodality are not particularly common, 
and that bimodality simply increases the average interval 
between episodes depending on the relative intensity of 
the two peaks and the gap between the two rainy seasons.
A limitation in scope is that the model used does not 
include the impact of ACT in different settings on the 
development of drug resistance. Long-acting ACT may 
be more vulnerable to development of resistance because 
sub-therapeutic concentrations of anti-malarials may per-
sist for long periods after treatment, although this is not 
the only factor that is important [43]. Targeting long-act-
ing ACT to areas where transmission is seasonal may help 
to reduce the rate at which resistance develops, by reduc-
ing the number of children who are exposed to reinfection 
while carrying sub-therapeutic concentrations of these 
drugs [44], and may help to prolong their useful life.
Conclusion
Areas of seasonal malaria transmission are likely to have 
more episodes of malaria that are preventable by switch-
ing to a long-acting drug for case management than areas 
of equivalent transmission spread more evenly over the 
year. This suggests that long-acting ACT should be con-
sidered carefully as an option for case-management in 
areas where malaria transmission is seasonal, particularly 
where malaria transmission is high.
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